HAVANA, March 25 (Xinhua) -- Cuban-made monoclonal antibody Nimotuzumab, widely considered as a "promising" cancer treatment, has been registered in 28 countries, the official daily Granma reported Tuesday.
The antibody has proven effective in treating malignant tumors in the head and neck, and is also being applied in cases of colorectal oncogenic disease, liver and lung cancer, brain metastases and other diseases, the daily reported, citing specialists at Cuba's Immunology Molecular Center.
Key figures in the field of medical biotechnology research around the globe have validated the treatment, the paper said.
To showcase the results of Nimotuzumab efficacy trials and the treatment's new indications, the seventh Scientific Global Meeting on Nimotuzumab opened Tuesday at the Havana Convention Center.
The forum, which will last through Thursday, brings together more than 200 experts from 20 countries and regions, and representatives of some 20 international biopharmaceutical companies interested in sharing their experiences with the drug, which is also used in oncology, oncopediatrics, radiotherapy, neurosurgery and pediatrics.